AAFMAA Wealth Management & Trust LLC Sells 1,215 Shares of Stryker Co. (NYSE:SYK)

AAFMAA Wealth Management & Trust LLC lowered its position in shares of Stryker Co. (NYSE:SYK) by 18.1% during the first quarter, HoldingsChannel.com reports. The fund owned 5,486 shares of the medical technology company’s stock after selling 1,215 shares during the quarter. Stryker accounts for about 0.9% of AAFMAA Wealth Management & Trust LLC’s holdings, making the stock its 26th biggest position. AAFMAA Wealth Management & Trust LLC’s holdings in Stryker were worth $2,042,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of the company. J. W. Coons Advisors LLC raised its stake in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock worth $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC grew its stake in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after acquiring an additional 27 shares during the period. Opal Wealth Advisors LLC increased its holdings in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after acquiring an additional 28 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after acquiring an additional 28 shares in the last quarter. Finally, Capital & Planning LLC raised its position in shares of Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after purchasing an additional 29 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $384.15 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company’s 50 day moving average price is $370.10 and its two-hundred day moving average price is $376.03. The stock has a market cap of $146.63 billion, a P/E ratio of 49.50, a P/E/G ratio of 2.93 and a beta of 0.91. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period last year, the business posted $2.50 earnings per share. Stryker’s revenue was up 11.9% on a year-over-year basis. On average, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is 45.41%.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Evercore ISI dropped their price objective on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a “buy” rating in a research report on Monday, April 14th. Finally, Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $427.30.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.